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Paul Szabolcs,1 William J. Burlingham,2 Angus W. Thomson3INTRODUCTION
Solid organ transplantation (SOT) and hemato-
poietic cell transplantation (HCT) have developed
over the past 5 decades largely independent from
each other despite sharing biologic principles, an
almost identical repertoire of immunosuppressive
(IS) drugs, and biologic response modifiers to over-
come barriers of immune rejection between host and
donor. Long-term graft function and recipient survival
are the same primary endpoints for SOT and HCT. It
is remarkable that allogeneic tissues can exhibit physi-
ologic function in a host environment that may display
disparate HLA antigens, blood type, and other
immune response molecules. Long-term graft func-
tion after SOT in most cases requires life-long IS
medications to prevent rejection in sharp contrast
with HCT where most patients after 1 to 2 years
post-HCT will be able to become independent of
pharmacologic agents to avoid rejection or graft-
versus-host-disease (GVHD) and therefore reach
a clinical state of tolerance. The hallmark of tolerance
is specific unresponsiveness between host and graft tis-
sues in the absence of any IS drugs; however, an equally
significant tenet is the prerequisite freedom from in-
fections, reflecting immunocompetence that is identi-
fiable by protective immune responsiveness against
pathogens. The established mechanisms of transplan-
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6/j.bbmt.2011.11.005tral (thymic) and peripheral clonal deletion, anergy,
and immune regulation [1]. In the following three sec-
tions, clinical and mechanistic studies highlight some
of these mechanisms, as significant progress has been
achieved after HCT, kidney, and liver transplantation.
Excitingly, immunomodulatory strategies have re-
cently translated into clinical success by combining
HCT with living-donor SOT, using HCT as a means
to achieve tolerance [2].SECTION I. TOLERANCE IN BLOODAND
MARROW TRANSPLANTATION
Allogeneic blood and marrow transplantation is
performed with growing success worldwide as
highlighted by several centers reporting comparable
outcome after unrelated donor bone marrow trans-
plantation (BMT) and cord blood transplantation
that match the outcome of genotypically HLA-
matched sib recipients [3-5]. Although for many,
chronic GVHD remains a major barrier to achieving
a sufficiently high quality of life, those patients who
are successfully weaned off systemic IS not only
demonstrate freedom of underlying malignancy,
marrow failure, or primary immunodeficiency but
also achieve a state of transplantation tolerance [6].
Full-donor chimerism as a way to ‘‘protect from re-
lapse’’ is an oft-stated goal of transplanters caring for
leukemia patients. Nevertheless, not all patients re-
quire 100% of their hematopoietic and immune cells
to be of donor origin, in particular, those with nonma-
lignant disorders. Long-term stable coexistence of
host and donor cells without clinical evidence of
immune-mediated pathology is often referred as persis-
tent mixed chimerism. It existed long before the ad-
vances of reduced-intensity conditioning. Despite
undergoing myeloablative conditioning, a sizeable
proportion of patients with b-thalassemia [7] or sickle
cell disease [8] reconstitute with mixed host and donor
hematopoietic cells, each represented in excess of 10%
for many years. Similarly, infants with severe com-
bined immunodeficiency receiving HLA-disparate
marrow grafts have demonstrated a sustained mixture
of donor and host cells in the absence of GVHD orS193
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illustrated by ex-severe combined immunodeficiency
patients whose fractionated blood chimerism may dis-
play predominantly host B lymphocytes and myeloid
cells in contrast with overwhelmingly donor-derived
T cells, because of selective advantage of donor cells
over genetically defective host cells. The underlying
immune mechanisms responsible for the absence of al-
loreactive immunopathology in both full-donor and in
persistent mixed chimerism is increasingly being char-
acterized. The presence of circulating T cells with im-
mune reactivity against host tissues even in the tolerant
state points to incomplete clonal deletion of newly
emerging thymocytes and/or indicating long-term
survival of adoptively transferred host-reactive T cells.
Nevertheless, peripheral regulatory mechanisms are
operational, as highlighted by the identification of
IL-10–secreting T regulatory cells (Tregs) and other
regulatory T- and B-lymphocytes [6]. Recently,
CD41/CD251/FoxP31 Tregs have entered the clini-
cal arena with an encouraging safety profile; however,
their efficacy in restoring immune tolerance, that is,
successful treatment ofGVHD, has not yet been estab-
lished [9].
A novel approach for achieving tolerance and
immune competence is illustrated by the recent
unique case of a 17-year-old patient with combined
immunodeficiency disease who required bilateral
orthotopic lung transplantation to treat pulmonary
failure caused by recurrent bacterial (Stenotropho-
monas, Escherichia coli) and mycobacterial pneumonia.
Chronic hypoxia and recurrent infectious gastroen-
teritis led to severe growth failure necessitating total
parental nutrition for years. She presented in 2009
with the clinical necessity for lung and hematopoietic
transplantations to correct pulmonary insufficiency
and the underlying combined immunodeficiency dis-
ease. At this age, her lymphocytes had declined to
a stage of extreme lymphopenia of T and B cells
(30-70 CD31 T cells/mm3) but normal natural-killer
cell numbers.
A single-patient protocol proposing the use of
a lung and BMT from the same donor to reduce the
probability of pulmonary graft rejection or GVHD
of the lungs was approved by Duke University institu-
tional review board and FDA (IDE #14206). A 4 of
8-HLA-matched unrelated cadaveric donor was iden-
tified by the United Network for Organ Sharing, who
underwent iliac crest marrow harvest yielding 5.4 
108 cells/kg. Lungs were procured and transplanted
following the marrow harvest. The marrow was
cryopreserved following CD3 and CD19 depletion.
Bilateral orthotopic lung transplantation was per-
formed in December 2009 following pulse steroids
and basiliximab. Within days, the patient became in-
dependent of supplemental oxygen. Three months
later, while receiving FK506 and low-dose predni-sone, she underwent conditioning with rituximab,
alemtuzumab, antithymocyte globulin, hydroxyurea,
a dose of Thiotepa, and a single fraction of total-
body irridiation (lung shielding) before infusion of
the T cell-depleted thawed bone marrow. She was
discharged on day 120 on FK506 monotherapy
with outstanding performance status and full-donor
chimerism in whole blood, CD31 T cell, and
CD151 myeloid cell fractions. She has remained
without detectable host leukocytes—last tested at 15
months post-BMT. Serial repeat lung biopsies have
shown absence of immune rejection. Severe gut
GVHD developed in September 2010 following
a bout of norovirus gastroenteritis and an associated
drop in FK506 levels. GVHD resolved after a single
dose of infliximab and low-dose steroid therapy; how-
ever, her course was complicated by enterococcus
sepsis and DIC. FK506 wean was started 1 year
post-BMT and completed by 15 months after
BMT. The pretransplantation lymphopenia has re-
solved, and since age 9 months post-BMT, her
CD41 cells are .250 cells/mm3. CD81 cells have
been .500 cells/mm3 since 3 months post-BMT
with associated significant anticytomegalovirus pro-
liferative responses (stimulation index .10). Func-
tional B cell recovery is evident with normal serum
IgA levels. Thymic output has been slow and became
detectable only at last testing (15 months post-BMT)
when the percentage of CD41 T cells dually express-
ing CD45RA and CD62L rose to 4%. Biological
studies were performed at 12 months posttransplanta-
tion to test for alloreactivity. Highly purified
peripheral blood (donor) T cells showed hyporeactiv-
ity (proliferation, IL-2 and tumor necrosis factor
secretion) against host-derived Epstein-Barr virus-
transformed B cell lines compared with Epstein-
Barr virus-lymphoblastic cell lines generated from
haplotype mismatched maternal (\7%) or fully mis-
matched unrelated donor (\5%). This ‘‘tolerant’’
state could not be broken by in vitro Treg depletion
and neither HLA class I or II blockade led to further
attenuation of self-reactivity. There is no detectable
IL-10 in coculture supernatants. Taken together, in
this T cell-depleted BMT setting, the ancillary im-
mune data support a central clonal deletion mecha-
nism to explain the lack of antirecipient reactivity.
In sum, this unique case shows for the first time, the
feasibility and immune consequences of tandem ca-
daveric lung and T cell-depleted marrow transplanta-
tion from the same HLA-mismatched unrelated
donor to create solid organ and recipient-specific tol-
erance and fully functional donor-derived hematopoi-
etic, immune, and pulmonary organ function in the
absence of systemic immunosuppression. However,
with all leukocytes of donor origin, it cannot be deter-
mined if there is a threshold prerequisite for donor
cell chimerism to achieve tolerance.
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AND TREGS IN TOLERANCE TO RENAL
TRANSPLANTATIONS
The Clinical Progress of Kidney Transplantation
Human kidney transplantation for end-stage renal
disease was facilitated by existence of two kidneys per
individual. Because just one can be life-sustaining, kid-
ney transplantation could originate as a living donor
procedure. The first successful transplantations were
done in identical twins in the mid-1950s, and later,
as corticosteroids (Pred) and azathioprine (Aza) began
to be applied in the early 1960s, transplantations were
extended to HLA-identical siblings and to HLA-
mismatched family members. Although cadaveric
kidney transplantations were made possible by the
Aza-Pred immunosuppressive drug combination, the
advent of the T cell inhibitory agent cyclosporine A
in the 1980s, greatly increased the volume and success
rate of transplantations from deceased donors. The
problem of chronic rejection, known variously as
chronic allograft nephropathy and interstitial fibrosis
and tubular atrophy (IF/TA), persisted into the cyclo-
sporine and tacrolimus era and remains the major
cause of late graft failure for both live-donor and
deceased-donor transplantations. Major histocompat-
ibility complex (MHC) typing is routinely performed
in kidney transplantation, and patient and graft sur-
vival have benefited from high degrees of HLA match-
ing, in particular for HLA class II (DR and DQ)
antigens. Because of late graft losses and return to
the transplantation waiting list for a second or third
transplantation, anti-HLA antibody formation and
its sequelae, antibody-mediated rejection, have
emerged as major clinical problems, requiring careful
attention to HLA mismatches and various strategies
to suppress or eliminate antibody-forming cells. Fi-
nally, it appears that the long-term reliance on calci-
neurin inhibitors for chronic IS is a recipe for
nephrotoxicity and end-stage renal disease. A solution
to the three-headed problem of chronic IS toxicity,
donor-specific HLA antibody formation, and chronic
rejection lies in the generation of stable immune toler-
ance, the long-sought ‘‘Holy Grail’’ of transplantation
immunology. However, even short of this lofty goal,
one might envision ‘‘leveraging’’ some degree of toler-
ance at the T and B cell level to achieve long-term sta-
ble graft function under minimal IS therapy.
Direct versus Indirect Alloreactivity
T cells profoundly affect the outcome of both solid
organ and BMTs. These T cells are of two general
types: (1) high-frequency ‘‘direct pathway’’ alloreactive
T cells, specific for nominal antigens in the context of
self-MHC molecules, but because of cross-reactivity
to a foreignMHC/peptide, are able to respond directly
to donor antigen-presenting cells (APCs); and (2)low-frequency ‘‘indirect pathway’’ alloreactive T cells,
recognizing peptides derived from the donor MHC,
but processed and presented by host dendritic cells
(DCs). The latter are similar to classic T cells that
respond to processed self- and viral antigens, and
thus are expected to be highly integrated into the reg-
ulatory system of the host. Althoughmany studies have
examined direct pathway T cells detected by the
in vitro mixed lymphocyte reaction assay, the role of
indirect pathway T cells in human tolerance has not
been extensively investigated. The following two stud-
ies yielded new insights into the host-donor relation-
ship in renal transplantation, based entirely on the
indirect pathway T cell response.
Posttansplantation studies
(Haynes L. et al., Donor-specific indirect pathway
analysis reveals a B cell-independent signature which
reflects outcomes in kidney transplant recipients. Am
J Transplant. In press).
To investigate the role of donor-specific indirect
pathway T cells in renal transplantation tolerance,
we used the trans-vivo delayed-type hypersensitivity
assay to analyze peripheral blood mononuclear cells
of subjects enrolled in the Immune Tolerance Net-
work*-sponsored Registry of Tolerant Kidney
Transplant recipients (ITN507ST). The trans-vivo
delayed-type hypersensitivity test provides an index
of cell-mediated immunity, without exposing the
transplantation patient directly to the challenge anti-
gens (Ag). It involves the transfer of human peripheral
blood mononuclear cells plus Ag (donor allo-Ag or re-
call Ag such as tetanus toxoid or cytomegalovirus) into
the pinnae or footpads of naive mice. This induces
a quantifiable delayed-type hypersensitivity-like swell-
ing response that is Ag-specific and requires prior Ag
sensitization. The assay offers a simple, reliable clinical
monitoring device and also a model with which to
study mechanisms underlying the regulation of host
immune responses. Subjects (n 5 45) were enrolled
into five groups: identical twin, clinically tolerant
(TOL), steroid monotherapy (Mono), standard immu-
nosuppression (SI), and chronic rejection (CR), based
on transplantation type, posttransplantation immuno-
suppression, and graft function. The indirect pathway
was active in all groups except twins, but distinct inter-
group differences were evident, corresponding to
clinical status. The antidonor indirect pathway
T effector response increased across patient groups
(TOL\Mono\SI\CR; P\ .0001), whereas anti-
donor indirect pathway T regulatory response
decreased (TOL . Mono 5 SI . CR; P \ .005).
This pattern differed from that seen in circulating
naive B cell numbers and in a B cell-based cross-plat-
form biomarker analysis. In these studies, some of
which were reported previously [10,11], patients on
steroid monotherapy were not ranked closest to
Table 1. Outcomes at 3 Years by LR Renal Transplantation Type and Pretransplantation Regulation Status
HLA Match Regulation Combined % Inhibition Creatinine (mg/dL) GFR (mL/min/1.73 m2) Graft Loss DSA Class I DSA Class II
Identical n 5 7 Mutual 142 ± 9.2 1.26 ± 0.29 59 ± 18.3 0/7 – –
1-Haplo n 5 9 Mutual 103 ± 32.1 1.20 ± 0.15 60 ± 13.9 0/9 2/9 0/9
1-Haplo n 5 9 One-way or none 49 ± 22.4 3.86a ± 2.86 32a ± 21.2 4/9b 4/9 5/9
DSA indicates donor-specific antibody; GFR, glomerular filtration rate.
aP < .03 versus 1 haplo mutual regulators.
bOne because of BK virus; three because of chronic rejection.
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from chronically rejecting patients. Cross-sectional
analysis of the indirect pathway revealed a spectrum
in T regulatory:T effector balance, ranging from
TOL patients having predominantly regulatory
(transforming growth factor-b) responses, to CR
patients having predominantly effector (inteferon-g
and IL-17A) responses to donor antigens. Therefore,
the indirect pathway measurements reflect a distinct
aspect of tolerance from the recently reported eleva-
tion of circulating naive B cells [10], which was
apparent only in recipients off immunosuppression.
Pretransplantation studies
(Jankowska-Gan et al. Pre-transplant immune
regulation predicts allograft outcome: bidirectional
regulation correlates with excellent renal transplant
function in living-related donor-recipient pairs.Trans-
plantation. In press).
Background
Partially outbred mice with multilineage, multior-
gan maternal microchimerism can spontaneously
accept heart allografts from a maternal-type donor.
We recently found that the ‘‘tolerance-prone’’ and
‘‘rejection-prone’’ mice in a given litter can be pre-
dicted by evaluating pretransplantation immune status
toward noninherited maternal antigens. To apply this
insight to clinical transplantation between family
members, we considered two alternative possibilities:
that transplantation evokes (1) a ‘‘one-way’’ interaction
of host T and B cells with APC and parenchymal cells
of a ‘‘passive’’ organ, or (2) a ‘‘two-way’’ interaction in
which graft passenger T cells and APC profoundly
influence the posttransplantation course. The latter
concept was originally proposed by Starzl in 1993
[12], an era when apoptosis and anergy mechanisms
were known, but the relevance of Tregs to transplanta-
tion outcome was still unknown.
Approach
To test these hypotheses, we conducted a 3-year
pilot clinical trial in 25 renal transplantation patients
and their living donors under standard (HLA-ID sib)
or Campath-1H induction (HLA 1 haplomissmatched
and LURD) therapy and calcineurin inhibitor-based
maintenance IS regimens. The % inhibition of recallresponse in the presence of donor or recipient cell ly-
sate was determined 1 day before transplantation by
trans-vivo delayed-type hypersensitivity assay, as
a measure of familial antigen-specific Tr status.
Results
Peripheral blood mononuclear cells of 7 HLA-
identical D-R pairs, had strong preransplantation
(50%-75%) bystander inhibition in both host-versus-
graft and graft-versus-host directions, resulting in
a mean combined inhibition value of 142%. All had
excellent 3-year outcome. In contrast, only half the
HLA-haploidentical pairs (9 of 18) had mutual regula-
tion pretransplantation, whereas the rest had either
one-way or no regulation. Mutual regulators had 3-
year graft survival indistinguishable from that of
HLA-identical siblings, with no rejections or donor-
specific antibody, whereas nonmutual regulators had
relatively poor outcomes in a depletional regimen
(Table 1).
Conclusion
The data are consistent with a two-way paradigm,
warranting a wider study of pretransplantation regula-
tion and investigation of the regulatory or effector
properties of passenger leukocytes in renal transplanta-
tions. If confirmed, these results profoundly shift the
focus in organ transplantation from posttransplanta-
tion, recipient-only toward pretransplantation, recipi-
ent and donor immunologic evaluation—including,
for example, the relevance of donor autoreactivity to
collagen V in lung transplantation.
The Immune Tolerance Network
The Immune Tolerance Network (ITN) is an
international clinical research consortium founded by
the National Institutes of Health in 2000, whose mis-
sion is to accelerate the clinical development of immune
tolerance therapies through a unique development
model. The mission is broad enough to include toler-
ance approaches in autoimmune diabetes and in
asthma, in addition to solid organ transplantation. In
fact, out of the 20 clinical trials and registries currently
listed on the ITN Website, http://www.immune
tolerance.org/professionals/about-us, five are kidney
transplantation related, three are liver-transplantation
related, and the remaining 12 are autoimmunity and
Biol Blood Marrow Transplant 18:S193-S200, 2012 S197Tolerance after SOTand HCTasthma related. The ITN is currently evaluating new
proposals to combine kidney and stem cell transplanta-
tions from the same donor to achieve immunologic tol-
erance in patients with end-stage renal disease.
Although results of pilot studies at Massachusetts Gen-
eralHospital [13] and StanfordUniversity [14] utilizing
such approaches have already shown great promise in
inducing lasting stable tolerance, more research will
be needed to ensure safety and efficacy, particularly as
these approaches move from HLA-identical siblings
toHLA-mismatched live donors andfinally to deceased
donor transplantations.We feel that our research in the
area of indirect pathway alloreactivity and pretrans-
plantation regulation can play a role in patient selection
for such trials and in evaluation of other tolerance ap-
proaches, such as the current EU-sponsored ONE
study http://www.onestudy.org/, that aims tominimize
immunosuppression by substituting in vitro-generated
regulatory cells for standard immunosuppressive drugs.
(Please see supplemental data at the end of Section III
listing active ITN studies.)SECTION III. LIVER TRANSPLANTATIONS
AND THEIR INHERENT TOLEROGENICITY,
MECHANISTIC INSIGHTS, AND
IMPLICATIONS
The Uniqueness of Liver Transplantation
Human liver transplantation was an experimental
procedure, with poor 1-year patient survival (approx
25%) until the 1980s. With the advent of the T cell in-
hibitory agent cyclosporine A, outcomes improved
markedly, and liver transplantation became standard
treatment for end-stage liver disease. One-year patient
survival is now as high as 85% to 90%, with 50%
15-year patient survival. In liver transplantation,
allograft rejection does not contribute to late graft
failure to the same extent as with other types of organ
graft. The chronic shortage of deceased donor livers
justifies the practices of split liver and live donor liver
transplantation, the latter including ABO-incompati-
ble transplantation. Unlike with other commonly
transplanted organs, MHC typing is not routinely
performed in liver transplantation, although some
patient populations have benefited from high degrees
of HLA matching.
The liver displays a number of features that distin-
guish it from other organ grafts, including its unique
architecture and anatomic location downstream of
the gut, its pattern of blood flow, and its regenerative
and hematopoietic capacity. It has an unusual constit-
uency of immune cells, including comparatively large
numbers of innate immune cells and a range of poten-
tially tolerogenic APCs [15]. Each of these factors
contributes to a unique microenvironment that deter-
mines the success of liver transplantation. Of specialsignificance, both to basic science and clinical liver
transplantation management, is the liver’s inherent
tolerogenicity, which is greater than that of other or-
gans. In mice and in certain rat strain combinations,
fully MHC-mismatched hepatic allografts are ac-
cepted without host immunosuppressive therapy and
induce donor-specific tolerance [16]. Liver allografts
are also accepted without antirejection therapy in
larger animals (pigs); whereas in humans, the liver
can afford a protective effect against rejection of other
organs transplanted concomitantly or subsequently
from the same donor.
There are well-documented reports of human liver
allograft recipients (especially those who underwent
transplantation as children) who have ceased to take
antirejection drugs (because of infectious complica-
tions, drug toxicities, patient noncompliance, or
physician-controlled weaning) and who have not re-
jected their transplantations up tomany years postdrug
withdrawal [17]. Several trials have assessed the feasi-
bility of discontinuing all immunosuppressive drugs
under physician supervision. This approach has been
successful in approximately 20% of patients [18].
These patients offer valuable investigative material
for analysis of the mechanistic basis of clinical organ
transplantation tolerance and the potential identifica-
tion of a tolerance ‘‘gene signature’’ [19]. These studies
also offer the prospect of developing an assay(s) that
can identify liver transplantation recipients who can
discontinue immunosuppressive therapy.Hematopoietic Cell Microchimerism in Liver
Allograft Recipients
In rodents, the liver is an important hematopoietic
organ. Indeed, in lethally irradiated rats, full reconsti-
tution of hematopoietic cell lineages can be achieved
by syngeneic liver transplantation [20]. In humans,
hematopoietic cells of the transplanted liver are
capable of inducing acute GVHD in 1% to 2% of
immunosuppressed recipients [21]. Recently, com-
plete hematopoietic chimerism and tolerance of an
HLA-mismatched liver allograft from a deceased
male donor was reported in a female child, with no
evidence of GVHD, 17 months after liver transplanta-
tion [22]. Notably, in 1992/1993, Starzl et al. [12]
made the original observation of persistent multiline-
age hematopoietic cell microchimerism (defined as
\1% donor cells) in both lymphoid and nonlymphoid
tissues of long-surviving liver or kidney graft recipi-
ents, including patients off immunosuppression for
many years posttransplantation. These findings pro-
vided the basis for the hypothesis that persistent mi-
crochimerism might be an important determinant of
long-term graft survival and transplantation tolerance.
The mechanism envisaged was mutual exhaustion of
immune reactivity, with ensuing clonal deletion of
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tensive investigative work in small animal models to
further ascertain the nature of the chimeric cells and
their functional significance and the dependence of
transplantation tolerance on microchimerism [23]. In
addition, clinical studies were undertaken to evaluate
the potential benefit of deliberate augmentation of chi-
merism in conventionally treated liver and other allo-
graft recipients by donor BM cell infusion [24].
Liver-Derived DCs and Regulation of Allograft
Outcome: The Concept of Tolerogenic DC
In studies of the function of donor-derived hema-
topoietic cells in liver transplantation, the DC became
the focus of attention because of the ability of this
important migratory APC to traffick from the liver
to host lymphoid tissue and regulate alloimmune
responses. Following liver transplantation in mice,
immature donor-derived DC could be propagated
from the BM of nonimmunosuppressed graft recipi-
ents that became tolerant to the donor [25]. The pres-
ence and persistence of these cells in host lymphoid
tissues raised key questions regarding their functional
significance. Importantly, infusion of immature liver-
derived DC into prospective pancreatic islet allograft
recipients could prolong transplantation survival
[26]. These findings and their implications constituted
a paradigm shift from the established perception, at the
time (early 1990s), of DC solely as instigators of organ
allograft rejection, to cells with ability to regulate (allo)
immunity. Moreover, they prompted many subse-
quent studies that have validated the ability of Tolero-
genic DC (tol DC) to promote tolerance in preclinical
models [27]. Tol DC therapy is highly effective in the
prevention of lethal GVHD and leukemia relapse fol-
lowing experimental allogeneic BM cell transplanta-
tion in animals with leukemia [28]. Currently,
clinical grade human tol DC are being generated for
potential therapeutic use in transplantation and auto-
immune disease [29].
Tol DC-Treg Interaction and the Promotion/
Maintenance of Tolerance
Tol DCs can promote the survival/proliferation of
Tregs at the expense of effector T cells. In turn, Tregs
can exert effects on DCs that promote their tolero-
genic properties [30]. Both tol DCs and Tregs have
been implicated in experimental liver transplantation
tolerance in the absence of immunosuppressive drug
therapy [22], whereas elevations in Treg have been
documented in clinically tolerant human liver allograft
recipients [31,32]. Of particular note is the potential of
DCs for the generation/expansion of allo-Ag-specific
Tregs with ability to suppress allo-Ag-specific effector
T cell responses, thus sparing those effector T cells
able to combat infection/mediate antitumor immu-nity. Although initial phase 1 clinical trials of Treg
for the prevention of GVHD in recipients of cord
blood transplantations have used polyclonal Tregs
expanded using anti-CD3/CD28 monoclonal Abs
and IL-2 [33], future studies of Treg cell therapy are
also likely to employ allo-Ag-specific Tregs generated
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Ongoing clinical trials listed at the ITN Web site:
1. Promoting Tolerance to Peanut in High-Risk
Children (LEAP)
Principal Investigator:
Gideon Lack, Evelina Children’s Hospital, London,
UK2. Promoting Tolerance to Common Allergens in
High-Risk Children: Global Prevention of Asthma in
Children (GPAC) Study
Principal Investigator:
Patrick Holt, University of Western Australia, Perth,
AUS
Peter Sly, Telethon Institute for Child Health
Research, Perth, AUS
3. Campath-1H/Tacrolimus/SirolimusWithdrawal in
Renal Transplantation
Principal Investigator:
Stuart Knechtle, University of Wisconsin, Madison,
WI
4. Belatacept to Prevent Organ Rejection in Kidney
Transplant Patients
Principal Investigator:
Flavio Vincenti, University of California, San
Francisco, CA
Christian Larsen,MD, EmoryUniversity, Atlanta, GA
5. Safety and Efficacy of Campath-1H and Tacrolimus
followed by Immunosuppression Withdrawal in Liver
Transplantation
Principal Investigator:
J. Richard Thistlethwaite, University of Chicago, IL
6. Gradual Withdrawal of Immunosuppression in
Patients Receiving a Liver Transplant (AWISH)
Principal Investigator:
Abraham Shaked, University of Pennsylvania,
Philidelphia, PA
7. Immunosuppression Withdrawal for Pediatric
Living-Donor Liver Transplant Recipients (WISP-R)
Principal Investigator:
Sandy Feng, University of California, San Francisco
8. A Phase II Study of Multiple Doses of hOKT3g-
1(Ala-Ala) for New Onset Type 1 Diabetes (AbATE)
Principal Investigator:
Kevan Herold, Yale University, New Haven, CT
9. Study of Thymoglobulin to Arrest Type 1 Diabetes
(START)
Principal Investigator:
Stephen Gitelman, University of California, San
Francisco
10. A Phase I Trial of IL-2 and Sirolimus in Recent-
Onset Type 1 Diabetes Mellitus
Principal Investigator:
Carla Greenbaum, Virginia Mason Research Center
11. ITN Registry of Tolerant Kidney Transplant
Recipients
Principal Investigator:
Kenneth Newell, Emory University
12. Cytokine Production in Blood Leukocytes of
Prediabetic Children and Effect of Intranasal Insulin
Principal Investigator:
Jorma Ilonen, University of Turku, Finland
13. Effects of Intravenous Alpha-1 Antitrypsin on
Preserving Beta-Cell Function in New-Onset Type 1
Diabetes Mellitus
S200 Biol Blood Marrow Transplant 18:S193-S200, 2012P. Szabolcs et al.Principal Investigator:
Gordon Weir, Joslin Diabetes Center, Boston, MA
14. A Cooperative Clinical Study of Abatacept in Mul-
tiple Sclerosis (ACCLAIM)
Principal Investigator:
Samia Khoury, Harvard Medical School, Boston, MA
15. AnObservational Study to Assess the Prevalence of
a Tolerance Signature in Renal Transplant Recipients
(ARTIST)
Principal Investigator:
Kenneth Newell, Emory University, Atlanta, GA
Laurence Turka, Harvard Medical School, Boston,
MA
Anil Chandraker, Harvard Medical School, Boston,
MA
16. Abatacept and Cyclophosphamide Combination:
Efficacy and Safety Study (ACCESS) for Lupus
Nephritis
Principal Investigator:
David Wofsy, University of California San Francisco,
CABetty Diamond, Feinstein Institute, Manhasset, NY
17. High-Dose Immunosuppression and Autologous
Transplantation for Multiple Sclerosis (HALT MS)
Principal Investigator:
Richard A. Nash, Fred Hutchinson Cancer Research
Center, Seattle, WA
18. Renal Allograft Tolerance through Mixed
Chimerism
Principal Investigator:
David H. Sachs, MD, Harvard Medical School
19. A Screening Study for Identification of Tolerance
Markers in Liver Transplant Recipients Who Re-
ceived Campath-1H Immunosuppression
Principal Investigator:
Andreas Tzakis, MD, Jackson Memorial Hospital
Panagiotis Tryphonopoulos, MD, University of
Miami
20. Inducing Remission in Type 1 Diabetes with
Alefacept (T1DAL)
Principal Investigator:
Mark Rigby, Emory University, Atlanta, GA
